Most pharmaceutical companies have one business unit that represents the company. These units, which usually own specialized cardiovascular, anticancer, or antiviral products, or have flagship products that lead their respective markets, are often revered within the company as well.

Janssen Korea’s Immunology Business Unit is one such unit. The company, which had been leading the central nervous system (CNS) area until the mid-2000s, made its way into the immunology business with ‘Remicade (infliximab)’ and provided various treatment options including ‘Stelara (ustekinumab),’ ‘Tremfya (guselkumab),’ and ‘Simponi (golimumab),’ rising to lead the immunology treatment paradigm. The drugs